Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gefitinib + metformin
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of gefitinib, an EGFR tyrosine kinase inhibitor, and metformin, a biguanide antidiabetic drug. This combination has been investigated primarily for non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations, with the aim of overcoming resistance to EGFR-TKIs. The combination works by targeting both the EGFR signaling pathway (via gefitinib) and the IGF-1R signaling pathway (via metformin).
- Other names
- metformin hydrochloridegefitinib
02
Targets
EGFR (Epidermal growth factor receptor)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on gefitinib + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gefitinib + metformin.